BR112022010638A2 - Compostos para modular a atividade de fxr e usos dos mesmos - Google Patents

Compostos para modular a atividade de fxr e usos dos mesmos

Info

Publication number
BR112022010638A2
BR112022010638A2 BR112022010638A BR112022010638A BR112022010638A2 BR 112022010638 A2 BR112022010638 A2 BR 112022010638A2 BR 112022010638 A BR112022010638 A BR 112022010638A BR 112022010638 A BR112022010638 A BR 112022010638A BR 112022010638 A2 BR112022010638 A2 BR 112022010638A2
Authority
BR
Brazil
Prior art keywords
compounds
fxr activity
activity
modulate fxr
modulate
Prior art date
Application number
BR112022010638A
Other languages
English (en)
Inventor
Yang Bailing
Kristjan Gudmundsson
Dong Liuyu
Chen James
Original Assignee
Gannex Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gannex Pharma Co Ltd filed Critical Gannex Pharma Co Ltd
Publication of BR112022010638A2 publication Critical patent/BR112022010638A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

COMPOSTOS PARA MODULAR A ATIVIDADE DE FXR E USOS DOS MESMOS. Trata-se um composto para modular a atividade de FXR que tem uma estrutura de fórmula (I), um sal farmaceuticamente aceitável, um éster ou um estereoisômero do mesmo.
BR112022010638A 2019-12-03 2020-10-12 Compostos para modular a atividade de fxr e usos dos mesmos BR112022010638A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/122595 WO2021108974A1 (en) 2019-12-03 2019-12-03 Compounds for modulating activity of fxr and uses thereof
PCT/CN2020/120369 WO2021109712A1 (en) 2019-12-03 2020-10-12 Compounds for modulating activity of fxr and uses thereof

Publications (1)

Publication Number Publication Date
BR112022010638A2 true BR112022010638A2 (pt) 2022-08-16

Family

ID=76111005

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022010638A BR112022010638A2 (pt) 2019-12-03 2020-10-12 Compostos para modular a atividade de fxr e usos dos mesmos
BR112022010798A BR112022010798A2 (pt) 2019-12-03 2020-10-12 Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022010798A BR112022010798A2 (pt) 2019-12-03 2020-10-12 Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo

Country Status (13)

Country Link
US (2) US20230165843A1 (pt)
EP (2) EP4073070A4 (pt)
JP (2) JP7430263B2 (pt)
KR (2) KR20220112278A (pt)
CN (2) CN112891348B (pt)
AU (2) AU2020395393B2 (pt)
BR (2) BR112022010638A2 (pt)
CA (2) CA3163779A1 (pt)
CO (2) CO2022008719A2 (pt)
IL (2) IL293507A (pt)
MX (2) MX2022006653A (pt)
PE (2) PE20230235A1 (pt)
WO (3) WO2021108974A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021108974A1 (en) * 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
TW202317110A (zh) * 2021-07-06 2023-05-01 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
TW202315608A (zh) * 2021-07-06 2023-04-16 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
WO2023035181A1 (en) * 2021-09-09 2023-03-16 Gannex Pharma Co., Ltd. A pharmaceutical composition of fxr agonist and its preparation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013946A (es) 2007-07-02 2010-03-10 Glaxosmithkline Llc Agonistas del receptor de farnesoide x.
RS61540B1 (sr) * 2013-09-11 2021-04-29 Inst Nat Sante Rech Med Postupci i farmaceutske kompozicije za tretiranje infekcije hepatitis b virusa
EP3193869A1 (en) * 2014-08-14 2017-07-26 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Perk activator for the treatment of neurodegenerative diseases
US10080743B2 (en) * 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) * 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2018190643A1 (en) * 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. An isoxazole derivatives as nuclear receptor agonists and used thereof
US10829486B2 (en) * 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2021108974A1 (en) * 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof

Also Published As

Publication number Publication date
CA3163779A1 (en) 2021-06-10
AU2020395393A1 (en) 2022-06-23
JP7430263B2 (ja) 2024-02-09
PE20230182A1 (es) 2023-02-01
CO2022008701A2 (es) 2022-07-19
MX2022006653A (es) 2022-07-05
AU2020395393B2 (en) 2023-07-06
CN112891348A (zh) 2021-06-04
WO2021108974A1 (en) 2021-06-10
US20220388997A1 (en) 2022-12-08
WO2021109713A1 (en) 2021-06-10
MX2022006742A (es) 2022-08-15
BR112022010798A2 (pt) 2022-08-23
KR20220112278A (ko) 2022-08-10
AU2020397245B2 (en) 2024-02-29
PE20230235A1 (es) 2023-02-07
CN112898289B (zh) 2022-11-04
AU2020397245A1 (en) 2022-06-30
IL293507A (en) 2022-08-01
EP4073071A1 (en) 2022-10-19
JP2023505205A (ja) 2023-02-08
EP4073071A4 (en) 2023-11-01
CA3159899A1 (en) 2021-06-10
CN112898289A (zh) 2021-06-04
JP2023504690A (ja) 2023-02-06
EP4073070A1 (en) 2022-10-19
WO2021109712A1 (en) 2021-06-10
KR20220101697A (ko) 2022-07-19
EP4073070A4 (en) 2023-10-18
CO2022008719A2 (es) 2022-07-19
CN112891348B (zh) 2022-06-28
US20230165843A1 (en) 2023-06-01
IL293497A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
BR112022010638A2 (pt) Compostos para modular a atividade de fxr e usos dos mesmos
BR112021021718A2 (pt) Moduladores de thr-ss e métodos de uso dos mesmos
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
BR112021024131A2 (pt) Derivado de anel inibidor de btk, método de preparação para o mesmo e aplicação farmacêutica do mesmo
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
CO2018014167A2 (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos
BR112012019199A2 (pt) derivados de 4-(n-azacicloalquil) anilidas como moduladores de canais de potássio.
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
CO2021008018A2 (es) Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CO2020004669A2 (es) Derivados de bencimidazol y sus usos
BR112016002384A2 (pt) composto, composição de herbicida, método para controlar plantas indesejáveis, e, uso de um composto
BR112022011892A2 (pt) Composições farmacêuticas intranasais de inibidores de cgrp
BR112016002383A2 (pt) composto, composição herbicida, método para controlar plantas indesejáveis, e, uso de um composto
CL2021002946A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
BR112021011325A2 (pt) Derivados de rapamicina
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
CL2018003553A1 (es) Composición y sistema para atraer insectos lepidópteros. (divisional solicitud 201703168)
CL2023001139A1 (es) Compuestos moduladores del cftr, composiciones y usos de estos
BR112018015257A2 (pt) composição para formação de alfa-gel e uma composição de alfa-gel